Bioscience Across the North to Benefit from New United Life Sciences Collaboration
Bionow, the BioIndustry Association (BIA), BioPartner and One Nucleus (ON) has announced the formation of United Life Sciences, a strategic partnership representing more than 1000 life science and healthcare members across the UK and internationally. The aim of the partnership is to work together on a range of matters that directly benefit members including Bionow’s members in the north of the UK and the wider UK sector.
Today the partnership also publishes the Life Sciences Manifesto 2015–2020, which is being launched at the BIA’s UK Bioscience Forum in London. Led by the BIA, the four organisations have worked closely together on the Manifesto to pinpoint the key issues for the sector and make policy recommendations to government. Its three core messages to policy makers are
• Retain focus on strategically important technologies such as regenerative medicine and synthetic biology, which hold great potential to benefit the UK economy.
• Ensure a supportive tax and finance environment through continuing policies such as the Biomedical Catalyst, R&D Tax Credits and the Patent Box.
• Support new flexible routes to licensing, evaluation, uptake and reimbursement of cutting edge medicines and treatments to facilitate swift patient access. A centrally funded and reimbursed Early Access to Medicines Scheme and full utilisation of the European Medicine Agency’s Adaptive Licensing pilot will be required to achieve this aim.
Going forward United Life Sciences will
• Hold a series of UK roadshows to enable early stage companies access capital, understand the evolving policy landscape and grow their businesses.
• Promote and provide discounts for members on each other’s events.
• Work together to provide a combined approach at large international events.
The group has been working closely together informally for 2 years, and has already hosted several joint events both in the UK and overseas. The partnership will also be seeking new ways to collaborate with others in the sector.
Announcing the new partnership, Harriet Fear, CEO of One Nucleus, said: “Collaboration and partnership based on mutual respect and trust are the key hallmarks of successful organisations in bioscience and United Life Sciences works in this way too — it’s in my DNA to support the UK after 21 years of serving my country as a diplomat. Collaboration, as so many of our members are aware, is vitally important.”
Dr Geoff Davison, CEO of Bionow, said: “By working together we avoid duplication of effort, recognising that all our members are stretched in terms of their time and resources, plus it recognises the strengths and expertise of each of the four organisations. The partnership is totally focused upon and driven by the needs of the sector and representing over 1000 businesses means the group has international critical mass and clout.”
Steve Bates, CEO of the BIA, said: “Through this collaboration, all four organisations are fully committed to providing a united front and critically, one voice, to the government via the lobbying and advocacy work that the BIA undertakes for the sector.”
Lin Bateson, Executive Director of Biopartner UK, said: “Linking up to provide a combined approach will help to focus international attention on UK bioscience expertise to encourage growth, inward investment, and much-needed funding.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance